Artigo de periodico

Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial (2013)

• Authors:
  • Steg, Philippe Gabriel
  • Mehta, Shamir R.
  • Pollack Jr, Charles V.
  • Bode, Christoph
  • Cohen, Marc
  • French, William J.
  • Hoekstra, James
  • Rao, Sunil V.
  • Ruzyllo, Witold
  • Ruiz-Nodar, Juan M.
  • Sabaté, Manel
  • Widimsky, Petr
  • Kiss, Robert Gabor
  • Estrada, Jose Luis Navarro
  • Hod, Hanoch
  • Kerkar, Prafulla
  • Guneri, Sema
  • Sezer, Murat
  • Ruda, Mikhail
  • Nicolau, José Carlos
  • Cavallini, Claudio
  • Ebrahim, Iftikhar
  • Petrov, Ivo
  • Kim, Jae-Hyung
  • Jeong, Myung-Ho
  • Lopez, Gabriel Arturo Ramos
  • Laanmets, Peep
  • Kovar, Frantisek
  • Gaudin, Christophe
  • Fanouillere, Karen C.
  • Minini, Pascal
  • Hoffman, Elaine B.
  • Moryusef, Angele
  • Wiviott, Stephen D.
  • Sabatine, Marc S.
• Autor USP: NICOLAU, JOSÉ CARLOS - FM
• Unidade: FM
• DOI: 10.1001/jama.2013.277165
• Subjects: ANTICOAGULANTES; ISQUEMIA; DOENÇA AGUDA; CORONARIOPATIA (TERAPIA)
• Language: Inglês
• Imprenta:
  • Publisher place: Chicago
  • Date published: 2013
• Source:
  • Título: JAMA: Journal of the American Medical Association
  • ISSN: 0098-7484
  • Volume/Número/Paginação/Ano: v. 310, n. 11, p. 1145-1155, 2013

Informações sobre o DOI: 10.1001/jama.2013.277165 (Fonte: oaDOI API)
• Este periódico é de assinatura
• Este artigo NÃO é de acesso aberto
  
• Cor do Acesso Aberto: closed

---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  STEG, Philippe Gabriel et al. Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial. JAMA: Journal of the American Medical Association, v. 310, n. 11, p. 1145-1155, 2013Tradução . . Disponível em: https://doi.org/10.1001/jama.2013.277165. Acesso em: 11 out. 2024.

• APA

  Steg, P. G., Mehta, S. R., Pollack Jr, C. V., Bode, C., Cohen, M., French, W. J., et al. (2013). Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial. JAMA: Journal of the American Medical Association, 310( 11), 1145-1155. doi:10.1001/jama.2013.277165

• NLM

  Steg PG, Mehta SR, Pollack Jr CV, Bode C, Cohen M, French WJ, Hoekstra J, Rao SV, Ruzyllo W, Ruiz-Nodar JM, Sabaté M, Widimsky P, Kiss RG, Estrada JLN, Hod H, Kerkar P, Guneri S, Sezer M, Ruda M, Nicolau JC, Cavallini C, Ebrahim I, Petrov I, Kim J-H, Jeong M-H, Lopez GAR, Laanmets P, Kovar F, Gaudin C, Fanouillere KC, Minini P, Hoffman EB, Moryusef A, Wiviott SD, Sabatine MS. Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial [Internet]. JAMA: Journal of the American Medical Association. 2013 ; 310( 11): 1145-1155.[citado 2024 out. 11 ] Available from: https://doi.org/10.1001/jama.2013.277165

• Vancouver

  Steg PG, Mehta SR, Pollack Jr CV, Bode C, Cohen M, French WJ, Hoekstra J, Rao SV, Ruzyllo W, Ruiz-Nodar JM, Sabaté M, Widimsky P, Kiss RG, Estrada JLN, Hod H, Kerkar P, Guneri S, Sezer M, Ruda M, Nicolau JC, Cavallini C, Ebrahim I, Petrov I, Kim J-H, Jeong M-H, Lopez GAR, Laanmets P, Kovar F, Gaudin C, Fanouillere KC, Minini P, Hoffman EB, Moryusef A, Wiviott SD, Sabatine MS. Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial [Internet]. JAMA: Journal of the American Medical Association. 2013 ; 310( 11): 1145-1155.[citado 2024 out. 11 ] Available from: https://doi.org/10.1001/jama.2013.277165

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
• Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
• Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
• Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
• Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
• Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
• Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
• Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
• Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
• Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study